Two percent of pediatric malignancies arise primarily in the liver; roughly 60% of these
cancers are hepatoblastoma (HB). Despite the rarity of these cases, international …

Hepatoblastoma, the most prevalent pediatric liver cancer, almost always carries a WNT-
activating CTNNB1 mutation, yet exhibits notable molecular heterogeneity. To characterize …

Introduction Inflammation is closely associated with tumor development and patient
prognosis. The objective of this study is to assess the prognostic value of the preoperative …

Liver tumors account for approximately 1%–2% of all pediatric malignancies, with the two
most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC) …

Background In the treatment of resectable hepatoblastoma (HB), it has not been established
whether upfront surgery (UF) at diagnosis or neoadjuvant chemotherapy and delayed …

Hepatoblastoma, the most prevalent pediatric liver cancer, almost always carries a WNT-
activating CTNNB1 mutation, yet exhibits notable molecular heterogeneity. To characterize …

Background We retrospectively investigated the role of neoadjuvant chemotherapy in low‐
risk patients with hepatoblastoma (HB) who underwent curative resection between February …

Background Specific patients with hepatoblastoma (HB) and hepatocellular carcinoma
(HCC) do not meet eligibility criteria for Children's Oncology Group (COG) trials, limiting an …

Abstract Introduction The Children's Hepatic Tumors International Collaboration (CHIC)
previously developed the CHIC hepatoblastoma risk stratification (CHIC-HS) model by …

Pediatric solid tumors represent a diverse group of malignancies that, despite consistent
threads across diagnosis and treatment, require individualized, multidisciplinary care. Over …